Total Payments
$31,049
2024 Payments
$29,290
Companies
11
Transactions
62
Medicare Patients
576
Medicare Billing
$80,342
Payment Breakdown by Category
Other$24,878 (80.1%)
Travel$3,040 (9.8%)
Food & Beverage$2,799 (9.0%)
Education$331.02 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,878 | 7 | 80.1% |
| Travel and Lodging | $3,040 | 7 | 9.8% |
| Food and Beverage | $2,799 | 45 | 9.0% |
| Education | $331.02 | 3 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $28,945 | 24 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $586.57 | 12 | $0 (2024) |
| Clovis Oncology, Inc. | $412.57 | 4 | $0 (2021) |
| TESARO, Inc. | $240.42 | 4 | $0 (2019) |
| Stryker Corporation | $224.92 | 2 | $0 (2021) |
| Foundation Medicine, Inc. | $205.85 | 5 | $0 (2023) |
| Genentech USA, Inc. | $126.78 | 1 | $0 (2019) |
| Merck Sharp & Dohme LLC | $124.03 | 6 | $0 (2024) |
| Seattle Genetics, Inc. | $104.15 | 1 | $0 (2019) |
| GlaxoSmithKline, LLC. | $52.82 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,290 | 32 | ABBVIE INC. ($28,945) |
| 2023 | $237.94 | 9 | AstraZeneca Pharmaceuticals LP ($121.47) |
| 2022 | $267.83 | 7 | Foundation Medicine, Inc. ($155.33) |
| 2021 | $445.03 | 5 | Stryker Corporation ($224.92) |
| 2019 | $807.67 | 9 | Clovis Oncology, Inc. ($336.32) |
All Payment Transactions
62 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,854.00 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | In-kind items and services | $422.72 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: Oncology | ||||||
| 11/14/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,754.00 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,854.00 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | In-kind items and services | $522.45 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $121.36 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,854.00 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | In-kind items and services | $662.58 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $130.20 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $23.07 | General |
| Category: Oncology | ||||||
| 09/06/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,854.00 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | In-kind items and services | $464.69 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $124.26 | General |
| Category: ONCOLOGY | ||||||
| 06/24/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,854.00 | General |
| Category: ONCOLOGY | ||||||
| 06/24/2024 | ABBVIE INC. | ELAHERE (Drug) | Travel and Lodging | Cash or cash equivalent | $626.45 | General |
| Category: ONCOLOGY | ||||||
| 06/24/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $139.99 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.88 | General |
| Category: ONCOLOGY | ||||||
| 05/15/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $24.96 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2024 | ABBVIE INC. | ELAHERE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,854.00 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $105.43 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 375 | 10,151 | $321,245 | $48,268 |
| 2022 | 10 | 190 | 4,427 | $183,334 | $29,970 |
| 2021 | 1 | 11 | 11 | $6,875 | $2,105 |
Total Patients
576
Total Services
14,589
Medicare Billing
$80,342
Procedure Codes
29
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 54 | 114 | $36,822 | $11,101 | 30.1% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2023 | 11 | 11 | $57,002 | $8,947 | 15.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 40 | 70 | $65,800 | $7,685 | 11.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 26 | 44 | $19,096 | $6,572 | 34.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 30 | 30 | $18,750 | $5,155 | 27.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 11 | 16 | $4,976 | $1,628 | 32.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 17 | 31 | $14,384 | $1,618 | 11.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 14 | 21 | $4,557 | $1,421 | 31.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 26 | 90 | $12,870 | $1,142 | 8.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 11 | 33 | $7,095 | $755.76 | 10.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 18 | 29 | $5,887 | $704.12 | 12.0% |
| J9267 | Injection, paclitaxel, 1 mg | Office | 2023 | 15 | 5,310 | $10,620 | $481.67 | 4.5% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 15 | 3,450 | $24,150 | $409.45 | 1.7% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2023 | 15 | 200 | $18,800 | $371.25 | 2.0% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 17 | 260 | $19,760 | $204.71 | 1.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 23 | 390 | $390.00 | $37.81 | 9.7% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 16 | 26 | $104.00 | $19.75 | 19.0% |
| J3490 | Unclassified drugs | Office | 2023 | 16 | 26 | $182.00 | $15.58 | 8.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 36 | 91 | $29,393 | $8,667 | 29.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 20 | 51 | $47,940 | $5,977 | 12.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 28 | 28 | $17,500 | $5,063 | 28.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 22 | 29 | $12,586 | $4,446 | 35.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 43 | $9,331 | $2,553 | 27.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 11 | 29 | $13,456 | $1,653 | 12.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 13 | 66 | $9,438 | $894.55 | 9.5% |
About Dr. Emily Hinchcliff, M.D
Dr. Emily Hinchcliff, M.D is a Gynecologic Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/14/2013. The National Provider Identifier (NPI) number assigned to this provider is 1558707877.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Emily Hinchcliff, M.D has received a total of $31,049 in payments from pharmaceutical and medical device companies, with $29,290 received in 2024. These payments were reported across 62 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($24,878).
As a Medicare-enrolled provider, Hinchcliff has provided services to 576 Medicare beneficiaries, totaling 14,589 services with total Medicare billing of $80,342. Data is available for 3 years (2021–2023), covering 29 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Other Specialties Gynecologic Oncology
- Location Chicago, IL
- Active Since 05/14/2013
- Last Updated 09/23/2021
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1558707877
Products in Payments
- ELAHERE (Drug) $28,945
- LYNPARZA (Drug) $463.65
- Rubraca (Drug) $412.57
- ZEJULA (Drug) $265.38
- FOUNDATIONONE (Device) $155.33
- Avastin (Biological) $126.78
- KEYTRUDA (Biological) $124.03
- SPY-PHI SYSTEM (Device) $53.93
- ENHERTU (Biological) $38.39
- JEMPERLI (Biological) $27.86
- FLOSEAL (Device) $25.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecologic Oncology Doctors in Chicago
Dr. Amina Ahmed, Md, MD
Gynecologic Oncology — Payments: $865,298
Gynecologic Oncology $865,298
Dario Roque, Md, MD
Gynecologic Oncology — Payments: $449,686
Gynecologic Oncology $449,686
Dr. Jenna Marcus, M.d, M.D
Gynecologic Oncology — Payments: $195,339
Gynecologic Oncology $195,339
Dr. Summer Dewdney, M.d, M.D
Gynecologic Oncology — Payments: $55,875
Gynecologic Oncology $55,875
Wilberto Nieves Neira, Md, MD
Gynecologic Oncology — Payments: $20,077
Gynecologic Oncology $20,077
Kathryn Mills
Gynecologic Oncology — Payments: $19,680
Gynecologic Oncology $19,680